Global Frontier Pharma: Liver Cancer Report 2015 - Identifying and Commercializing First-in-Class Innovation

May 27, 2015, 16:59 ET from Research and Markets

DUBLIN, May 27, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/7fdzh7/frontier_pharma) has announced the addition of the "Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation" report to their offering.

 

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )


The liver cancer pipeline contains 238 products in active development, approximately 47% of which are first-in-class. The percentage of the pipeline devoted to innovative products is considerably larger than both the industry and oncology average, which is a promising sign for novel therapeutics reaching the liver cancer market.

The contrast between the market and pipeline is vast. Analysis showed that the market contains 70 products, the majority of which are generic formulations of chemotherapies that are not frequently used in treatment, particularly in advanced-stage patients. Nexavar (sorafenib) is the dominant therapeutic on the market, and is also the only targeted therapy that is in regular use for advanced-stage liver cancer patients. However, pipeline analysis revealed that targeted therapies aimed at the underlying oncogenic signaling pathways are under much greater focus in the pipeline than in the market. The success of targeted therapies across the oncology market as a whole implies that the diversity and innovation in the pipeline is a promising sign, with products currently in development having the potential to transform and improve the relatively open liver cancer market.

Alignment of First-in-Class Molecular Targets with Disease Causation

The available analysis identified substantial variation in the alignment of first-in-class products to underlying dysfunctional signaling at protein and genetic level. The first-in-class products were compared in an in-depth analysis using various parameters to measure the potential of each target, with the most promising targets being further substantiated by published clinical and scientific evidence. Results of the analysis suggested that first-in-class status is not a feature that, in its own right, will create a successful product. However, there are a large number of first-in-class products backed by clinical and Preclinical data that are exciting future prospects for the liver cancer market.

Analysis of Patent Data

The frequency at which companies apply for patents within the market helps to identify companies that are trying to establish themselves or increase their liver cancer market share. This information identifies not only potential competitors, but also companies that may seek strategic partnerships to enter drug development.

First-in-Class Products in Licensing and Co-Development Deals

The deals landscape for liver cancer has been relatively active in recent years, with 62 licensing deals and 23 co-development deals between 2006 and 2014. However, the number pertaining to first-in-class products is very low.

Key Topics Covered:

1 Tables & Figures

2 Executive Summary

3 The Case for Innovation

4 Clinical and Commercial Landscape

5 Assessment of Pipeline Product Innovation

6 Liver Cancer Patent Family Analysis

7 Signaling Network, Disease Causation and Innovation Alignment

8 First-in-Class Target Evaluation

9 Deals and Strategic Consolidations

10 Appendix

For more information visit http://www.researchandmarkets.com/research/7fdzh7/frontier_pharma


Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net


SOURCE Research and Markets